Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02081807 · ClinicalTrials.gov registry record
Sequential Expansion of Comparative Effectiveness of Anticoagulants
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 221,228
- Enrollment target
NCT02081807: Completed study, sponsored by Boehringer Ingelheim.
NCT02081807 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 221,228 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02081807 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 221,228 participants
- Enrollment target
Study Summary
This cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.
Primary Outcome
The rate of overall stroke (hemorrhagic, ischemic or stroke of uncertain classification ) in patients who are matched on propensity score and calendar quarter of initiation. Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort. The outcome definition includes following: As primary International Classification of Diseases, Ninth Revision (ICD-9) discharge diagnosis (Dx): 431
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221,228 participants |
| Start Date | 2014-03-07 |
| Est. Completion | 2017-11-01 |
What the finished NCT02081807 record still lists
NCT02081807 is an observational study that tracks outcomes without assigning an intervention. Its 221,228 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02081807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02081807 about?
NCT02081807 is a clinical study titled "Sequential Expansion of Comparative Effectiveness of Anticoagulants". This cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and da...
What is the current status of trial NCT02081807?
This trial is currently completed. The enrollment target is 221,228 participants. The study started on 2014-03-07. Estimated completion is 2017-11-01.
Who is sponsoring clinical trial NCT02081807?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI